GlassScriptPhysician profile
Sarah J Breen
NPI 1700386703
$759.37
in general payments reported to CMS, 2019-2025
25 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.80 · 2023: $40.20 · 2024: $121 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $60.89 | 2025 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $53.60 | 2023-2024 | Arista Ah Flexitip |
| Medtronic, INC. | $53.17 | 2025 | Minimed 780g |
| Amgen INC. | $43.89 | 2025 | Tavneos, Evenity |
| Calliditas Therapeutics US INC. | $42.79 | 2025 | Tarpeyo |
| Csl Behring | $37.80 | 2022 | |
| Solventum Corporation | $37.18 | 2024-2025 | Prevena, Prevena Restor Bellaform, V.A.C. Veraflo |
| Lilly USA, LLC | $35.79 | 2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2025 | |
| Merz Pharmaceuticals, LLC | $30.95 | 2025 | Xeomin |
| Alexion Pharmaceuticals, INC. | $30.66 | 2025 | Ultomiris |
| Integra Lifesciences Corporation | $30.05 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Novo Nordisk INC | $29.05 | 2025 | Rybelsus, Ozempic, Wegovy |
| Chiesi USA, INC. | $28.98 | 2025 | Mycapssa |
| Radius Health, INC. | $27.28 | 2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.18 | 2025 | Jardiance |
| Ferring Pharmaceuticals INC. | $24.39 | 2023 | Euflexxa |
| Astrazeneca Pharmaceuticals LP | $20.53 | 2025 | Farxiga |
| Kerecis Limited | $19.61 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Dexcom, INC. | $17.06 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $16.53 | 2025 | |
| Tandem Diabetes Care, INC. | $15.17 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Vertex Pharmaceuticals Incorporated | $14.79 | 2025 | |
| Travere Therapeutics, INC. | $14.67 | 2025 | |
| Vericel Corporation | $14.45 | 2024 | Maci |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.